Agenus Inc. (NASDAQ:AGEN – Get Rating) – Investment analysts at B. Riley dropped their FY2022 EPS estimates for Agenus in a research note issued to investors on Monday, November 14th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post earnings per share of ($0.88) for the year, down from their previous estimate of ($0.70). The consensus estimate for Agenus’ current full-year earnings is ($0.73) per share. B. Riley also issued estimates for Agenus’ Q4 2022 earnings at ($0.22) EPS, FY2023 earnings at ($0.71) EPS and FY2024 earnings at ($0.70) EPS.
Several other brokerages have also recently weighed in on AGEN. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday. Sumitomo Mitsui Financial Group assumed coverage on shares of Agenus in a report on Wednesday, September 28th. They issued an “outperform” rating and a $5.00 target price on the stock.
Agenus Stock Down 2.5 %
Institutional Trading of Agenus
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the first quarter worth approximately $25,000. Bank of Nova Scotia acquired a new position in shares of Agenus in the 1st quarter valued at $31,000. Commonwealth Equity Services LLC acquired a new position in shares of Agenus in the 3rd quarter valued at $26,000. Leisure Capital Management acquired a new position in shares of Agenus in the 3rd quarter valued at $26,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Agenus by 441.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 13,860 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 11,300 shares during the period. Institutional investors and hedge funds own 51.89% of the company’s stock.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.